Open Outbreak

Meningococcal meningitis

Also known as: meningitis, Neisseria meningitidis, meningococcal disease, invasive meningococcal disease, meningococcus

Meningococcal meningitis is a dangerous bacterial infection of the lining around the brain and spinal cord, caused by Neisseria meningitidis. The same germ can also cause bloodstream infection, often called invasive meningococcal disease. WHO outbreak reports describe spread from person to person through respiratory droplets, with higher risk where people are in very close contact, including mass gatherings. The disease can move fast, so early medical care matters. Vaccines exist, but protection depends on which meningococcal group is circulating. WHO reports from Africa show that vaccination against serogroup A greatly reduced that form of the disease, while other groups such as C and W have still caused outbreaks. Antibiotic treatment is available, but this page does not give a single overall fatality figure because the sources gathered here did not provide one that applies across all settings and serogroups. The heaviest outbreak burden in WHO notices is in the African meningitis belt, though imported and travel-linked cases can occur elsewhere.

Key facts

TransmissionPerson-to-person through respiratory droplets and close contact, as described by WHO outbreak reports.
Incubationunknown
Case fatalityunknown
Reproduction numberunknown
VaccineVaccines exist, including serogroup A programs and broader meningococcal vaccines; which vaccine is useful depends on the serogroup.
TreatmentAntibiotic treatment is available for acute bacterial meningitis and invasive meningococcal disease.
ReservoirHumans
Endemic regionsEspecially the African meningitis belt; travel-linked cases and outbreaks can occur in other regions.

Transmission

WHO describes meningococcal disease as spreading from person to person through respiratory droplets. In plain terms, that means germs can pass during close, repeated contact with an infected person or a carrier, especially in crowded settings. WHO’s 2025 notice about cases linked to Umrah says the risk is increased at mass gatherings because many people mix closely and come from different places. WHO’s 2015 Nigeria report also calls the disease highly contagious during epidemic periods in African countries. The sources gathered here do not give a single reliable reproduction number for this disease, so that figure is listed as unknown. The documents also do not give a firm incubation-period number in the returned text, so that is left unknown rather than guessed. The practical point is that crowding, close contact, and travel can help spread meningococci, and public health authorities watch these situations closely.

Symptoms and severity

Meningococcal meningitis is one form of meningococcal disease, and it can become life-threatening very quickly. The overview source describes early symptoms that can look like flu at first: fever, headache, neck stiffness, nausea, vomiting, sensitivity to light, and confusion. Some people also develop a purple rash that does not fade when pressed, which can be a warning sign of bloodstream infection. WHO outbreak reports repeatedly describe meningitis as a devastating disease and a major public-health challenge. The sources returned in this session do not provide one single overall fatality estimate that clearly applies to all meningococcal meningitis cases worldwide, so this page lists case fatality as unknown. What the sources do support is that severity can be high and that rapid progression is a major concern. Because symptoms can start in a non-specific way, delay in seeking care can be dangerous.

Treatment and vaccines

This disease is treatable, and vaccines are available, but the details matter. A review on acute bacterial meningitis confirms that antimicrobial treatment is a core part of management. Another review and ACIP recommendations show that several meningococcal vaccines exist, including conjugate vaccines for serogroups A, C, W, and Y, and separate vaccines used for serogroup B in some settings. WHO outbreak reports from Nigeria say the MenA conjugate vaccine led to a marked decline in serogroup A disease after large vaccination campaigns, but they also warn that other serogroups can still cause epidemics. That means vaccination can be very effective, yet no single vaccine covers every outbreak situation equally. The sources gathered here do not give one short, universal statement on how well each product works in every age group and region, so this page keeps to the broad conclusion: prompt antibiotics matter, and vaccine choice depends on the circulating serogroup and local policy.

Where it occurs

WHO outbreak history in this session points to the African meningitis belt as the main region of recurring large outbreaks. Notices mention Niger, Nigeria, Togo, Chad, Sudan, Uganda, Burkina Faso, the Democratic Republic of the Congo, and multi-country epidemic seasons across the belt. WHO’s 2013 report from the belt recorded suspected meningitis cases in 18 of 19 countries under enhanced surveillance that season. More recent WHO items also show that meningococcal disease is not confined to that region. In 2025, WHO reported invasive meningococcal disease linked to travel associated with Umrah in Saudi Arabia and in returning travelers from multiple countries. That pattern matters for readers: the disease is most strongly associated with recurrent epidemics in parts of sub-Saharan Africa, but imported cases and clusters can appear elsewhere, especially when international travel and crowded gatherings are involved. The natural reservoir listed here is humans, because the pathogen spreads between people rather than from an animal host in the sources reviewed.

Recent history

On this site’s archive, meningitis has 83 WHO notices or major pandemic records since 1996. The WHO items returned here show repeated meningococcal events over many years, especially in the African meningitis belt. Examples include Niger and Nigeria in 2015, Togo and Nigeria in 2017, and a WHO regional summary for the 2013 epidemic season. WHO said that from 2022-11-01 to 2023-01-27, Niger reported 559 meningitis cases, with most confirmed cases caused by Neisseria meningitidis serogroup C. WHO also reported in 2025 that Saudi Arabia notified invasive meningococcal disease cases, with additional travel-related cases in people returning from Umrah. Taken together, the archive shows that meningococcal meningitis is not a one-off event. It is a recurring public-health problem with changing serogroups over time. WHO’s recent tone is watchful rather than sensational: vaccination has reduced some forms, but continued surveillance is needed because epidemiology keeps shifting.

What to watch

The main warning signs are clear in the WHO material. First, watch for spread into new regions or travel-linked clusters, especially after mass gatherings; the 2025 Saudi Arabia notice shows why this matters. Second, watch for stronger evidence of sustained person-to-person spread in crowded settings, because WHO links transmission to respiratory droplets and close mixing. Third, watch for changes in serogroups. WHO notes that MenA vaccination reduced serogroup A disease, but other groups such as C and W have still caused outbreaks, so a shift in the dominant strain can change vaccine needs. Fourth, watch for limits in vaccine coverage or supply during outbreak response, because the right vaccine depends on the serogroup in circulation. Finally, watch for treatment or prevention problems in high-risk groups; the literature includes concern that some medically vulnerable people remain at high risk even after vaccination. Any combination of wider geographic spread, strain replacement, or gaps in vaccination would make this disease more concerning.

Updated